Amid leadership shift, Mirati plots label expansions

With a fresh $300 million and a leadership change at the top, Mirati has the opportunity to prove its best-in-class claims for KRAS inhibitor Krazati can translate to market-leading sales, and that first mover advantage isn’t everything in the precision oncology world. 

On Tuesday, Mirati Therapeutics Inc. (NASDAQ:MRTX) announced that CEO David Meek would be stepping down just two years after taking on the role. Founder and President Charles Baum will move back into the CEO role on an interim basis while the company looks for a permanent replacement. ...